13F HOLDINGS REPORT
Foresite Capital Management VI LLC
Quarter ended Q4 2025 · Filed February 17, 2026 · Accession 0001104659-26-015412
Total Value
$330.8M
Positions
12
Other Managers
0
Confidential Omitted
No
Holdings (12)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CG Oncology, Inc. | CGON | 2,221,474 | $92.2M | 27.88% |
| 2 | RAPT Therapeutics, Inc. | 75382E208 | 1,562,500 | $52.9M | 16.00% |
| 3 | ALUMIS INC. | ALMS | 4,247,670 | $41.5M | 12.53% |
| 4 | Centessa Pharmaceuticals plc | CNTA | 1,364,019 | $34.1M | 10.31% |
| 5 | Verastem, Inc. | VSTM | 3,135,120 | $24.2M | 7.32% |
| 6 | Denali Therapeutics Inc. | DNLI | 1,000,000 | $16.5M | 4.99% |
| 7 | Natera, Inc. | NTRA | 67,356 | $15.4M | 4.66% |
| 8 | AGIOS PHARMACEUTICALS, INC. | AGIO | 530,000 | $14.4M | 4.36% |
| 9 | Kymera Therapeutics, Inc. | KYMR | 146,332 | $11.4M | 3.44% |
| 10 | Atai Beckley N.V. | N0731H103 | 2,750,000 | $11.2M | 3.40% |
| 11 | Corvus Pharmaceuticals, Inc. | CRVS | 1,381,233 | $10.6M | 3.21% |
| 12 | Hinge Health, Inc. | HNGE | 135,000 | $6.3M | 1.90% |